Shares of Verastem, Inc. (NASDAQ:VSTM – Get Free Report) have received a consensus recommendation of “Buy” from the eight research firms that are covering the firm, Marketbeat reports. Eight analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have issued a report on the stock in the last year is $14.57.
A number of equities research analysts have recently commented on VSTM shares. Cantor Fitzgerald reiterated an “overweight” rating on shares of Verastem in a research note on Friday, October 18th. Royal Bank of Canada reiterated an “outperform” rating and issued a $13.00 target price on shares of Verastem in a research note on Friday, October 18th. Truist Financial reduced their target price on shares of Verastem from $18.00 to $15.00 and set a “buy” rating for the company in a research report on Tuesday, August 13th. StockNews.com raised shares of Verastem from a “sell” rating to a “hold” rating in a report on Monday, August 12th. Finally, HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Verastem in a report on Friday, October 18th.
Get Our Latest Report on Verastem
Hedge Funds Weigh In On Verastem
Verastem Price Performance
Verastem stock opened at $3.28 on Monday. Verastem has a 52 week low of $2.10 and a 52 week high of $14.22. The company’s 50 day moving average price is $2.74 and its two-hundred day moving average price is $4.89. The stock has a market cap of $83.07 million, a P/E ratio of -0.75 and a beta of 0.17. The company has a quick ratio of 3.28, a current ratio of 3.28 and a debt-to-equity ratio of 1.88.
Verastem (NASDAQ:VSTM – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.31) EPS for the quarter, topping analysts’ consensus estimates of ($1.06) by $0.75. The business had revenue of $10.00 million for the quarter. On average, equities analysts predict that Verastem will post -3.36 earnings per share for the current year.
Verastem Company Profile
Verastem, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformation, and survival of tumor cells; and Defactinib, an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase for various solid tumors.
Recommended Stories
- Five stocks we like better than Verastem
- How to invest in marijuana stocks in 7 stepsĀ
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- How to Find Undervalued Stocks
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- Best Stocks Under $5.00
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Verastem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verastem and related companies with MarketBeat.com's FREE daily email newsletter.